Industry Research Reports
Home > Reports > Chemical & Material > Global β-Nicotinamide Mononucleotide (NMN) Market Outlook, In‑Depth Analysis & Forecast to 2031
Global β-Nicotinamide Mononucleotide (NMN) Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Chemical & Material
Published Date: 2025-07-31
Pages: 141 Pages
Report ld: 4808488
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
β-Nicotinamide Mononucleotide (NMN) Market Size(US$)
CAGR 2025-2031
13.4%
Market Size,2031
USD 992
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 468 million
Market Forecast in 2031(Value)
US$ 992 million
CAGR
13.4%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global β-Nicotinamide Mononucleotide (NMN) market is projected to grow from US$ 418 million in 2024 to US$ 992 million by 2031, at a CAGR of 13.4% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis produced from nicotinamide through nicotinamide phosphoribosyltransferase (NAMPT) and also referred to as NMN or nicotinamide ribotide. In recent studies of NMN applications to prevention and diagnosis of age-dependent diseases such as diabetes, neurodegenerative disorder, cardiac disease etc., it has become one of hottest biomarkers on discussion for anti-aging, lately.
NMN is a precursor of nicotinamide adenine dinucleotide (NAD+), which plays a vital role in cell metabolism and energy production. As we age, the level of NAD+ in the human body gradually decreases, resulting in weakened cell metabolism, which in turn triggers a series of aging-related diseases. Therefore, increasing the level of NAD+ in the body by supplementing NMN has become a new way to fight aging and maintain good health.
With the general improvement of global health awareness and continuous breakthroughs in scientific research and technology, the growth momentum of the NMN market will continue to increase. In the future, the NMN market will achieve a deeper cross-border integration with other health industries such as biotechnology, precision medicine, and nutritional supplements, giving rise to a series of innovative products and service models to meet consumers' more personalized and precise health needs.
At present, nicotinamide mononucleotide (NMN) is still in the development stage. There are not many manufacturers in the global market, and consumers have weak awareness of its use, especially in developing countries. The demand is lower than that in developed countries around the world, but the demand in developing countries is growing rapidly. Leading giants have proposed expansion plans and increased production bases.
Nicotinamide mononucleotide (NMN) core manufacturers include GeneHarbor, Mirailab Bioscience, Maac10 Formulas, Herbalmax and Genex Formula. China is the largest production area, accounting for about 84% of the global market share, followed by North America and Japan. The downstream applications of nicotinamide mononucleotide include health products, cosmetics, etc. Globally, health products are the largest application market, and raw materials for health products account for 99% of the total sales of nicotinamide mononucleotide in 2023.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global β-Nicotinamide Mononucleotide (NMN) market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- GeneHarbor
- Herbalmax
- Genex Formulas
- Mirailab Bioscience
- Maac10 Formulas
- EffePharm
- Bontac
- CELFULL
- Kingdomway
- ABA Chemical
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Content ≥98%
- Content ＜98%
Segment by Application
- Health Care Products
- Cosmetics
- Others
CHAPTER OUTLINE
Chapter 1: Defines the β-Nicotinamide Mononucleotide (NMN) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to β-Nicotinamide Mononucleotide (NMN): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global β-Nicotinamide Mononucleotide (NMN) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Content ≥98%
1.2.3 Content ＜98%
1.3 Market Segmentation by Application
1.3.1 Global β-Nicotinamide Mononucleotide (NMN) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Health Care Products
1.3.3 Cosmetics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global β-Nicotinamide Mononucleotide (NMN) Revenue Estimates and Forecasts 2020-2031
2.2 Global β-Nicotinamide Mononucleotide (NMN) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global β-Nicotinamide Mononucleotide (NMN) Sales Estimates and Forecasts 2020-2031
2.4 Global β-Nicotinamide Mononucleotide (NMN) Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global β-Nicotinamide Mononucleotide (NMN) Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 China
3.4.3 Japan
4 Competition by Manufacturers
4.1 Global β-Nicotinamide Mononucleotide (NMN) Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global β-Nicotinamide Mononucleotide (NMN) Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 Content ≥98% Market Size by Manufacturers
4.5.2 Content ＜98% Market Size by Manufacturers
4.6 Global β-Nicotinamide Mononucleotide (NMN) Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global β-Nicotinamide Mononucleotide (NMN) Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global β-Nicotinamide Mononucleotide (NMN) Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global β-Nicotinamide Mononucleotide (NMN) Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global β-Nicotinamide Mononucleotide (NMN) Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Type (2020-2031)
7.4 North America β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America β-Nicotinamide Mononucleotide (NMN) Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Type (2020-2031)
8.4 Europe β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe β-Nicotinamide Mononucleotide (NMN) Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Type (2020-2031)
10.4 Central and South America β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America β-Nicotinamide Mononucleotide (NMN) Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 GeneHarbor
12.1.1 GeneHarbor Corporation Information
12.1.2 GeneHarbor Business Overview
12.1.3 GeneHarbor β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.1.4 GeneHarbor β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 GeneHarbor β-Nicotinamide Mononucleotide (NMN) Sales by Product in 2024
12.1.6 GeneHarbor β-Nicotinamide Mononucleotide (NMN) Sales by Application in 2024
12.1.7 GeneHarbor β-Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2024
12.1.8 GeneHarbor β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.1.9 GeneHarbor Recent Developments
12.2 Herbalmax
12.2.1 Herbalmax Corporation Information
12.2.2 Herbalmax Business Overview
12.2.3 Herbalmax β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.2.4 Herbalmax β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 Herbalmax β-Nicotinamide Mononucleotide (NMN) Sales by Product in 2024
12.2.6 Herbalmax β-Nicotinamide Mononucleotide (NMN) Sales by Application in 2024
12.2.7 Herbalmax β-Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2024
12.2.8 Herbalmax β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.2.9 Herbalmax Recent Developments
12.3 Genex Formulas
12.3.1 Genex Formulas Corporation Information
12.3.2 Genex Formulas Business Overview
12.3.3 Genex Formulas β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.3.4 Genex Formulas β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 Genex Formulas β-Nicotinamide Mononucleotide (NMN) Sales by Product in 2024
12.3.6 Genex Formulas β-Nicotinamide Mononucleotide (NMN) Sales by Application in 2024
12.3.7 Genex Formulas β-Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2024
12.3.8 Genex Formulas β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.3.9 Genex Formulas Recent Developments
12.4 Mirailab Bioscience
12.4.1 Mirailab Bioscience Corporation Information
12.4.2 Mirailab Bioscience Business Overview
12.4.3 Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.4.4 Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) Sales by Product in 2024
12.4.6 Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) Sales by Application in 2024
12.4.7 Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2024
12.4.8 Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.4.9 Mirailab Bioscience Recent Developments
12.5 Maac10 Formulas
12.5.1 Maac10 Formulas Corporation Information
12.5.2 Maac10 Formulas Business Overview
12.5.3 Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.5.4 Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) Sales by Product in 2024
12.5.6 Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) Sales by Application in 2024
12.5.7 Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) Sales by Geographic Area in 2024
12.5.8 Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
12.5.9 Maac10 Formulas Recent Developments
12.6 EffePharm
12.6.1 EffePharm Corporation Information
12.6.2 EffePharm Business Overview
12.6.3 EffePharm β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.6.4 EffePharm β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.6.5 EffePharm Recent Developments
12.7 Bontac
12.7.1 Bontac Corporation Information
12.7.2 Bontac Business Overview
12.7.3 Bontac β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.7.4 Bontac β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.7.5 Bontac Recent Developments
12.8 CELFULL
12.8.1 CELFULL Corporation Information
12.8.2 CELFULL Business Overview
12.8.3 CELFULL β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.8.4 CELFULL β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.8.5 CELFULL Recent Developments
12.9 Kingdomway
12.9.1 Kingdomway Corporation Information
12.9.2 Kingdomway Business Overview
12.9.3 Kingdomway β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.9.4 Kingdomway β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.9.5 Kingdomway Recent Developments
12.10 ABA Chemical
12.10.1 ABA Chemical Corporation Information
12.10.2 ABA Chemical Business Overview
12.10.3 ABA Chemical β-Nicotinamide Mononucleotide (NMN) Product Models, Descriptions and Specifications
12.10.4 ABA Chemical β-Nicotinamide Mononucleotide (NMN) Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.10.5 ABA Chemical Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 β-Nicotinamide Mononucleotide (NMN) Industry Chain
13.2 β-Nicotinamide Mononucleotide (NMN) Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 β-Nicotinamide Mononucleotide (NMN) Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 β-Nicotinamide Mononucleotide (NMN) Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 β-Nicotinamide Mononucleotide (NMN) Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global β-Nicotinamide Mononucleotide (NMN) Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global β-Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global β-Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global β-Nicotinamide Mononucleotide (NMN) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global β-Nicotinamide Mononucleotide (NMN) Sales by Region (2020-2025) & (Tons)
Table 8. Global β-Nicotinamide Mononucleotide (NMN) Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global β-Nicotinamide Mononucleotide (NMN) Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global β-Nicotinamide Mononucleotide (NMN) Production by Region (2020-2025) & (Tons)
Table 12. Global β-Nicotinamide Mononucleotide (NMN) Production by Region (2026-2031) & (Tons)
Table 13. Global β-Nicotinamide Mononucleotide (NMN) Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global β-Nicotinamide Mononucleotide (NMN) Sales Share by Manufacturers (2020-2025)
Table 15. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global β-Nicotinamide Mononucleotide (NMN) Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global β-Nicotinamide Mononucleotide (NMN) by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in β-Nicotinamide Mononucleotide (NMN) as of 2024)
Table 19. Global β-Nicotinamide Mononucleotide (NMN) Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global β-Nicotinamide Mononucleotide (NMN) Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Kg)
Table 21. Key Manufacturers β-Nicotinamide Mononucleotide (NMN) Manufacturing Base and Headquarters
Table 22. Global β-Nicotinamide Mononucleotide (NMN) Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global β-Nicotinamide Mononucleotide (NMN) Sales by Type (2020-2025) & (Tons)
Table 26. Global β-Nicotinamide Mononucleotide (NMN) Sales by Type (2026-2031) & (Tons)
Table 27. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global β-Nicotinamide Mononucleotide (NMN) ASP by Type (2020-2031) & (US$/Kg)
Table 30. Technical Specifications by Key Product Type
Table 31. Global β-Nicotinamide Mononucleotide (NMN) Sales by Application (2020-2025) & (Tons)
Table 32. Global β-Nicotinamide Mononucleotide (NMN) Sales by Application (2026-2031) & (Tons)
Table 33. β-Nicotinamide Mononucleotide (NMN) High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global β-Nicotinamide Mononucleotide (NMN) Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global β-Nicotinamide Mononucleotide (NMN) ASP by Application (2020-2031) & (US$/Kg)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America β-Nicotinamide Mononucleotide (NMN) Growth Accelerators and Market Barriers
Table 40. North America β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America β-Nicotinamide Mononucleotide (NMN) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe β-Nicotinamide Mononucleotide (NMN) Growth Accelerators and Market Barriers
Table 43. Europe β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe β-Nicotinamide Mononucleotide (NMN) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Growth Accelerators and Market Barriers
Table 48. Southeast Asia β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America β-Nicotinamide Mononucleotide (NMN) Investment Opportunities and Key Challenges
Table 50. Central and South America β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Investment Opportunities and Key Challenges
Table 52. Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. GeneHarbor Corporation Information
Table 54. GeneHarbor Description and Major Businesses
Table 55. GeneHarbor Product Models, Descriptions and Specifications
Table 56. GeneHarbor Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 57. GeneHarbor Sales Value Proportion by Product in 2024
Table 58. GeneHarbor Sales Value Proportion by Application in 2024
Table 59. GeneHarbor Sales Value Proportion by Geographic Area in 2024
Table 60. GeneHarbor β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 61. GeneHarbor Recent Developments
Table 62. Herbalmax Corporation Information
Table 63. Herbalmax Description and Major Businesses
Table 64. Herbalmax Product Models, Descriptions and Specifications
Table 65. Herbalmax Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 66. Herbalmax Sales Value Proportion by Product in 2024
Table 67. Herbalmax Sales Value Proportion by Application in 2024
Table 68. Herbalmax Sales Value Proportion by Geographic Area in 2024
Table 69. Herbalmax β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 70. Herbalmax Recent Developments
Table 71. Genex Formulas Corporation Information
Table 72. Genex Formulas Description and Major Businesses
Table 73. Genex Formulas Product Models, Descriptions and Specifications
Table 74. Genex Formulas Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 75. Genex Formulas Sales Value Proportion by Product in 2024
Table 76. Genex Formulas Sales Value Proportion by Application in 2024
Table 77. Genex Formulas Sales Value Proportion by Geographic Area in 2024
Table 78. Genex Formulas β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 79. Genex Formulas Recent Developments
Table 80. Mirailab Bioscience Corporation Information
Table 81. Mirailab Bioscience Description and Major Businesses
Table 82. Mirailab Bioscience Product Models, Descriptions and Specifications
Table 83. Mirailab Bioscience Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 84. Mirailab Bioscience Sales Value Proportion by Product in 2024
Table 85. Mirailab Bioscience Sales Value Proportion by Application in 2024
Table 86. Mirailab Bioscience Sales Value Proportion by Geographic Area in 2024
Table 87. Mirailab Bioscience β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 88. Mirailab Bioscience Recent Developments
Table 89. Maac10 Formulas Corporation Information
Table 90. Maac10 Formulas Description and Major Businesses
Table 91. Maac10 Formulas Product Models, Descriptions and Specifications
Table 92. Maac10 Formulas Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 93. Maac10 Formulas Sales Value Proportion by Product in 2024
Table 94. Maac10 Formulas Sales Value Proportion by Application in 2024
Table 95. Maac10 Formulas Sales Value Proportion by Geographic Area in 2024
Table 96. Maac10 Formulas β-Nicotinamide Mononucleotide (NMN) SWOT Analysis
Table 97. Maac10 Formulas Recent Developments
Table 98. EffePharm Corporation Information
Table 99. EffePharm Description and Major Businesses
Table 100. EffePharm Product Models, Descriptions and Specifications
Table 101. EffePharm Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 102. EffePharm Recent Developments
Table 103. Bontac Corporation Information
Table 104. Bontac Description and Major Businesses
Table 105. Bontac Product Models, Descriptions and Specifications
Table 106. Bontac Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 107. Bontac Recent Developments
Table 108. CELFULL Corporation Information
Table 109. CELFULL Description and Major Businesses
Table 110. CELFULL Product Models, Descriptions and Specifications
Table 111. CELFULL Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 112. CELFULL Recent Developments
Table 113. Kingdomway Corporation Information
Table 114. Kingdomway Description and Major Businesses
Table 115. Kingdomway Product Models, Descriptions and Specifications
Table 116. Kingdomway Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 117. Kingdomway Recent Developments
Table 118. ABA Chemical Corporation Information
Table 119. ABA Chemical Description and Major Businesses
Table 120. ABA Chemical Product Models, Descriptions and Specifications
Table 121. ABA Chemical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 122. ABA Chemical Recent Developments
Table 123. Key Raw Materials Distribution
Table 124. Raw Materials Key Suppliers
Table 125. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 126. Milestones in Production Technology Evolution
Table 127. Distributors List
Table 128. Market Trends and Market Evolution
Table 129. Market Drivers and Opportunities
Table 130. Market Challenges, Risks, and Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. β-Nicotinamide Mononucleotide (NMN) Product Picture
Figure 2. Global β-Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Content ≥98% Product Picture
Figure 4. Content ＜98% Product Picture
Figure 5. Global β-Nicotinamide Mononucleotide (NMN) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Health Care Products
Figure 7. Cosmetics
Figure 8. Others
Figure 9. β-Nicotinamide Mononucleotide (NMN) Report Years Considered
Figure 10. Global β-Nicotinamide Mononucleotide (NMN) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 12. Global β-Nicotinamide Mononucleotide (NMN) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global β-Nicotinamide Mononucleotide (NMN) Revenue Market Share by Region (2020-2031)
Figure 14. Global β-Nicotinamide Mononucleotide (NMN) Sales (2020-2031) & (Tons)
Figure 15. Global β-Nicotinamide Mononucleotide (NMN) Sales (CAGR) by Region (2020-2031) (Tons)
Figure 16. Global β-Nicotinamide Mononucleotide (NMN) Sales Market Share by Region (2020-2031)
Figure 17. Global β-Nicotinamide Mononucleotide (NMN) Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 18. Global β-Nicotinamide Mononucleotide (NMN) Production Trend by Region (2020-2031) (Tons)
Figure 19. Global β-Nicotinamide Mononucleotide (NMN) Production Market Share by Region (2020-2031)
Figure 20. Production Capacity Enablers & Constraints
Figure 21. β-Nicotinamide Mononucleotide (NMN) Production Growth Rate in North America (2020-2031) & (Tons)
Figure 22. β-Nicotinamide Mononucleotide (NMN) Production Growth Rate in China (2020-2031) & (Tons)
Figure 23. β-Nicotinamide Mononucleotide (NMN) Production Growth Rate in Japan (2020-2031) & (Tons)
Figure 24. Top 5 and Top 10 Manufacturers β-Nicotinamide Mononucleotide (NMN) Sales Volume Market Share in 2024
Figure 25. Global β-Nicotinamide Mononucleotide (NMN) Revenue Market Share Ranking (2024)
Figure 26. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 27. Content ≥98% Revenue Market Share by Manufacturer in 2024
Figure 28. Content ＜98% Revenue Market Share by Manufacturer in 2024
Figure 29. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 30. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 31. Global β-Nicotinamide Mononucleotide (NMN) Sales Market Share by Type (2020-2031)
Figure 32. Global β-Nicotinamide Mononucleotide (NMN) Revenue Market Share by Type (2020-2031)
Figure 33. Global β-Nicotinamide Mononucleotide (NMN) Sales Market Share by Application (2020-2031)
Figure 34. Global β-Nicotinamide Mononucleotide (NMN) Revenue Market Share by Application (2020-2031)
Figure 35. North America β-Nicotinamide Mononucleotide (NMN) Sales YoY (2020-2031) & (Tons)
Figure 36. North America β-Nicotinamide Mononucleotide (NMN) Revenue YoY (2020-2031) & (US$ Million)
Figure 37. North America Top 5 Manufacturers β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2024
Figure 38. North America β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Type (2020- 2031)
Figure 39. North America β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 40. North America β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2020-2031)
Figure 41. North America β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 42. US β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 43. Canada β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 44. Mexico β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 45. Europe β-Nicotinamide Mononucleotide (NMN) Sales YoY (2020-2031) & (Tons)
Figure 46. Europe β-Nicotinamide Mononucleotide (NMN) Revenue YoY (2020-2031) & (US$ Million)
Figure 47. Europe Top 5 Manufacturers β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2024
Figure 48. Europe β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Type (2020-2031)
Figure 49. Europe β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 50. Europe β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2020-2031)
Figure 51. Europe β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 52. Germany β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 53. France β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 54. U.K. β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 55. Italy β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 56. Russia β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 57. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales YoY (2020-2031) & (Tons)
Figure 58. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Asia-Pacific Top 8 Manufacturers β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2024
Figure 60. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Type (2020- 2031)
Figure 61. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 62. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2020-2031)
Figure 63. Asia-Pacific β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 64. Indonesia β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 65. Japan β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 66. South Korea β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 67. China Taiwan β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 68. India β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2031) & (US$ Million)
Figure 69. Central and South America β-Nicotinamide Mononucleotide (NMN) Sales YoY (2020-2031) & (Tons)
Figure 70. Central and South America β-Nicotinamide Mononucleotide (NMN) Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Central and South America Top 5 Manufacturers β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2024
Figure 72. Central and South America β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Type (2021-2031)
Figure 73. Central and South America β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Central and South America β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2020-2031)
Figure 75. Central and South America β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. Brazil β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2025) & (US$ Million)
Figure 77. Argentina β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2025) & (US$ Million)
Figure 78. Middle East, and Africa β-Nicotinamide Mononucleotide (NMN) Sales YoY (2020-2031) & (Tons)
Figure 79. Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Revenue YoY (2020-2031) & (US$ Million)
Figure 80. Middle East and Africa Top 5 Manufacturers β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) in 2024
Figure 81. Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Type (2021-2031)
Figure 82. South America β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 83. Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Sales Volume (Tons) by Application (2020-2031)
Figure 84. Middle East and Africa β-Nicotinamide Mononucleotide (NMN) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 85. GCC Countries β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2025) & (US$ Million)
Figure 86. Turkey β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2025) & (US$ Million)
Figure 87. Egypt β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2025) & (US$ Million)
Figure 88. South Africa β-Nicotinamide Mononucleotide (NMN) Revenue (2020-2025) & (US$ Million)
Figure 89. β-Nicotinamide Mononucleotide (NMN) Industry Chain Mapping
Figure 90. Regional β-Nicotinamide Mononucleotide (NMN) Manufacturing Base Distribution (%)
Figure 91. β-Nicotinamide Mononucleotide (NMN) Production Process
Figure 92. Regional β-Nicotinamide Mononucleotide (NMN) Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of β-Nicotinamide Mononucleotide (NMN) in 2031?
The global market size of β-Nicotinamide Mononucleotide (NMN) in 2031 was 992 Million USD.
What is the annual compound growth rate of the global β-Nicotinamide Mononucleotide (NMN) market size from 2025 to 2031?
Which companies rank high in the global β-Nicotinamide Mononucleotide (NMN) market?
Which region is expected to have the highest market share?
What was the global market size of β-Nicotinamide Mononucleotide (NMN) in 2025?
Related Reports
Global β-Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global β-Nicotinamide Mononucleotide (NMN) market size was US$ 468 million in 2025 and is forecast to reach a readjusted size of US$ 1112 million by 2032 with a CAGR of 13.4% during the forecast period 2026-2032.
Published Date: 2026-01-05
Pages: 76
USD 4250.00
(Single User License)
Global β-Nicotinamide Mononucleotide (NMN) Market Research Report 2026
The global β-Nicotinamide Mononucleotide (NMN) market was valued at US$ 468 million in 2025 and is anticipated to reach US$ 1112 million by 2032, at a CAGR of 13.4% from 2026 to 2032.
Published Date: 2026-01-05
Pages: 135
USD 2900.00
(Single User License)
β-Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for β-Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 468 million in 2025 and is projected to reach US$ 1112 million, growing at a CAGR of 13.4% from 2026 to 2032.
Published Date: 2026-01-05
Pages: 109
USD 3950.00
(Single User License)
Global β-Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global β-Nicotinamide Mononucleotide (NMN) market size was US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published Date: 2025-09-10
Pages: 79
USD 4250.00
(Single User License)
Global β-Nicotinamide Mononucleotide (NMN) Market Research Report 2025
The global market for β-Nicotinamide Mononucleotide (NMN) was valued at US$ 418 million in the year 2024 and is projected to reach a revised size of US$ 992 million by 2031, growing at a CAGR of 13.4% during the forecast period.
Published Date: 2025-02-09
Pages: 94
USD 2900.00
(Single User License)
β-Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for β-Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published Date: 2025-02-07
Pages: 94
USD 3950.00
(Single User License)
Global and China β-Nicotinamide Mononucleotide (NMN) Market Report & Forecast 2024-2030
The global β-Nicotinamide Mononucleotide (NMN) revenue was US$ 373 million in 2023 and is forecast to a readjusted size of US$ 886 million by 2030 with a CAGR of 13.4% during the review period (2024-2030).
Published Date: 2024-12-20
Pages: 102
USD 4350.00
(Single User License)
β-Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for β-Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 373 million in 2023 and is forecast to a readjusted size of US$ 886 million by 2030 with a CAGR of 13.4% during the forecast period 2024-2030.
Published Date: 2024-12-20
Pages: 101
USD 3950.00
(Single User License)
Global β-Nicotinamide Mononucleotide (NMN) Market Insights, Forecast to 2030
Valued at US$ 418 million in 2024, the global β-Nicotinamide Mononucleotide (NMN) market is forecast to reach US$ 886 million by 2030, at a CAGR of 13.4% during the forecast period.
Published Date: 2024-12-20
Pages: 131
USD 4900.00
(Single User License)
Global β-Nicotinamide Mononucleotide (NMN) Market Research Report 2024
The global market for β-Nicotinamide Mononucleotide (NMN) was valued at US$ 373 million in the year 2023 and is projected to reach a revised size of US$ 886 million by 2030, growing at a CAGR of 13.4% during the forecast period.
Published Date: 2024-12-20
Pages: 93
USD 2900.00
(Single User License)
Global β-Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global β-Nicotinamide Mononucleotide (NMN) market size was US$ 468 million in 2025 and is forecast to reach a readjusted size of US$ 1112 million by 2032 with a CAGR of 13.4% during the forecast period 2026-2032.
Published: 2026-01-05
Pages: 76
USD 4250.00 (Single User License)Global β-Nicotinamide Mononucleotide (NMN) Market Research Report 2026
The global β-Nicotinamide Mononucleotide (NMN) market was valued at US$ 468 million in 2025 and is anticipated to reach US$ 1112 million by 2032, at a CAGR of 13.4% from 2026 to 2032.
Published: 2026-01-05
Pages: 135
USD 2900.00 (Single User License)β-Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for β-Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 468 million in 2025 and is projected to reach US$ 1112 million, growing at a CAGR of 13.4% from 2026 to 2032.
Published: 2026-01-05
Pages: 109
USD 3950.00 (Single User License)Global β-Nicotinamide Mononucleotide (NMN) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global β-Nicotinamide Mononucleotide (NMN) market size was US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published: 2025-09-10
Pages: 79
USD 4250.00 (Single User License)Global β-Nicotinamide Mononucleotide (NMN) Market Research Report 2025
The global market for β-Nicotinamide Mononucleotide (NMN) was valued at US$ 418 million in the year 2024 and is projected to reach a revised size of US$ 992 million by 2031, growing at a CAGR of 13.4% during the forecast period.
Published: 2025-02-09
Pages: 94
USD 2900.00 (Single User License)β-Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for β-Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Published: 2025-02-07
Pages: 94
USD 3950.00 (Single User License)Global and China β-Nicotinamide Mononucleotide (NMN) Market Report & Forecast 2024-2030
The global β-Nicotinamide Mononucleotide (NMN) revenue was US$ 373 million in 2023 and is forecast to a readjusted size of US$ 886 million by 2030 with a CAGR of 13.4% during the review period (2024-2030).
Published: 2024-12-20
Pages: 102
USD 4350.00 (Single User License)β-Nicotinamide Mononucleotide (NMN)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for β-Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 373 million in 2023 and is forecast to a readjusted size of US$ 886 million by 2030 with a CAGR of 13.4% during the forecast period 2024-2030.
Published: 2024-12-20
Pages: 101
USD 3950.00 (Single User License)Global β-Nicotinamide Mononucleotide (NMN) Market Insights, Forecast to 2030
Valued at US$ 418 million in 2024, the global β-Nicotinamide Mononucleotide (NMN) market is forecast to reach US$ 886 million by 2030, at a CAGR of 13.4% during the forecast period.
Published: 2024-12-20
Pages: 131
USD 4900.00 (Single User License)Global β-Nicotinamide Mononucleotide (NMN) Market Research Report 2024
The global market for β-Nicotinamide Mononucleotide (NMN) was valued at US$ 373 million in the year 2023 and is projected to reach a revised size of US$ 886 million by 2030, growing at a CAGR of 13.4% during the forecast period.
Published: 2024-12-20
Pages: 93
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now